SUNWIN STEVIA INTERNATIONAL, INC. - Quarter Report: 2012 January (Form 10-Q)

suwn10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly report ended January 31, 2012

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to __________

Commission file number: 000-53595

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC.

(Exact name of registrant as specified in charter)

NEVADA	56-2416925
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6 SHENGWANG AVE., QUFU, SHANDONG, CHINA	273100
(Address of principal executive offices)	(Zip Code)

(86) 537-4424999

(Registrant's telephone number, including area code)

NOT APPLICABLE

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has been submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X].

Indicate the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: As of March 8, 2011 there were 157,356,137 shares of the registrant's common stock issued and outstanding.

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC. AND SUBSIDIARIES

FORM 10-Q

QUARTERLY PERIOD ENDED JANUARY 31, 2012

INDEX

	Page
PART I-FINANCIAL INFORMATION
Item 1. Financial Statements	1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3. Quantitative and Qualitative Disclosures About Market Risk	23

Item 4. Controls and Procedures	23

PART II-OTHER INFORMATION
Item 1. Legal Proceedings	24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3. Defaults Upon Senior Securities	24

Item 4. Mine Safety Disclosures	24

Item 5. Other Information	24

Item 6 - Exhibits	25

Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results

This report contains forward-looking statements. The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. A list of factors that could cause our actual results of operations and financial condition to differ materially is set forth below, and these factors are discussed in greater detail under Item 1A – "Risk Factors" in our Annual Report on Form 10-K for the year ended April 30, 2011 as filed with the Securities and Exchange Commission:


	-		Our revenues have declined in the past two fiscal years and there are no assurances they will return to historic levels in future periods;
	-		Dependence upon continued market acceptance of our stevioside products, maintaining Generally Recognized as Safe status in the United States and obtaining approval in other countries in the world that currently do not permit use of steviosides in food products;
	-		Competition and low barriers to entry to the market in which we sell our products;
	-		Our dependence on the services of our president;
	-		Our inability to control the cost of our raw materials;
	-		The limitation on our ability to receive and use our cash flows effectively as a result of restrictions on currency exchange in the PRC;
	-		Our operations are subject to government regulation. If we fail to comply with the applicable regulations, our ability to operate in future periods could be in jeopardy;
	-		The absence of various corporate governance measures which may reduce stockholders’ protections against interested director transactions, conflicts of interest and other matters;
	-		The effect of changes resulting from the political and economic policies of the Chinese government on our assets and operations located in the PRC;
	-		The impact of economic reform policies in the PRC;
	-		The influence of the Chinese government over the manner in which our Chinese subsidiaries must conduct our business activities;
	-		The impact of any natural disasters and health epidemics in China;
	-		Regulations relating to offshore investment activities by Chinese residents may increase the administrative burden we face and create regulatory uncertainties that may limit or adversely affect our ability to complete a business combination with PRC companies;
	-		The lack of various legal protections in certain agreements to which we are a party and which are material to our operations which are customarily contained in similar contracts prepared in the United States;
	-		Our ability to enforce our rights due to policies regarding the regulation of foreign investments in China;
	-		Difficulties stockholders may face who seek to enforce any judgment obtained in the United States against us, which may limit the remedies otherwise available to our stockholders;
	-		Our ability to comply with the United States Foreign Corrupt Practices Act which could subject us to penalties and other adverse consequences;
	-		Provisions of our articles of incorporation and bylaws may delay or prevent a take-over which may not be in the best interests of our stockholders;
	-		Adverse affects on the liquidity of our stock because it currently trades below $5.00 per share, is quoted on the OTC bulletin board, and is considered a “penny stock;” and
	-		The impact on our stock price due to future sales of restricted stock held by existing shareholders.

We caution that the factors described herein and other factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

INDEX OF CERTAIN DEFINED TERMS USED IN THIS REPORT

We are on a fiscal year ending April 30, as such the year ended April 30, 2011 is referred to as “fiscal 2011” and the year ending April 30, 2012 is referred to as “fiscal 2012.” Also, the three month period ending January 31, 2012 is our third quarter and is referred to as the “third quarter of fiscal 2012” the nine month period ending January 31, 2012 is referred to as the “first nine months of fiscal 2012". Likewise, the three month period ending January 31, 2011 is referred to as the “third quarter of fiscal 2011” the nine month period ending January 31, 2011 is referred to as the “first nine months of fiscal 2011”.

When used in this report, the terms:

	-	“Sunwin”, “we”, “us” and the “Company” refers to Sunwin International Neutraceuticals, Inc., a Nevada corporation, and our subsidiaries;

	-	“Sunwin Tech” refers to our wholly owned subsidiary Sunwin Tech Group, Inc., a Florida corporation;

	-	“Qufu Natural Green” refers to our wholly owned subsidiary Qufu Natural Green Engineering Co., Ltd., a Chinese limited liability company;

	-	“Shengya Veterinary Medicine” refers to, Shengya Veterinary Medicine Co., Ltd., a Chinese limited liability company, and a formerly wholly owned subsidiary of Qufu Natural Green, which was sold in July 2010;

	-	“Sunwin Stevia International” refers to our wholly owned subsidiary Sunwin Stevia International Corp., a Florida corporation, which was converted to Sunwin USA, LLC a Delaware limited liability company in May 2009;

	-	“Sunwin USA” refers to Sunwin USA, LLC, a Delaware limited liability company, a 55% owned equity method investment;

	-	“Sunwin Canada” refers to our formerly wholly owned subsidiary Sunwin (Canada) Pharmaceutical Ltd., a Canadian corporation, which was dissolved in August 2010

	-	“Qufu Shengwang” refers to Qufu Shengwang Stevia Biology and Science Co., Ltd., a Chinese limited liability company. Qufu Natural Green owns a 100% interest in Qufu Shengwang; and

	-	“Qufu Shengren” refers to Qufu Shengren Pharmaceutical Co., Ltd., a Chinese limited liability company, and a wholly owned subsidiary of Qufu Natural Green.

We also use the following terms when referring to certain related and other parties:

	-	“Pharmaceutical Corporation” refers to Shandong Shengwang Pharmaceutical Co., Ltd., a Chinese limited liability company which is controlled by Mr. Laiwang Zhang, President, Chairman and a principal shareholder of our company;

	-	“Shandong Group” refers to Shandong Shengwang Group Co., Ltd., a Chinese limited liability company, which is controlled by Mr. Laiwang Zhang, President, Chairman and a principal shareholder of our company; and

	-	“WILD Flavors” refers to WILD Flavors, Inc., a Delaware corporation.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	January 31, 2012			April 30, 2011
	(Unaudited)			(Audited)
ASSETS
CURRENT ASSETS:
Cash	$	242,049		$	10,563,413
Accounts receivable, net of allowance for doubtful accounts of $966,886 and $1,098,240, respectively		1,957,852			2,080,332
Accounts receivable - related party		480,626			204,664
Notes receivable		36,582			-
Loans receivable		3,508,261			505,260
Inventories, net		4,034,030			3,327,914
Due from related party		3,181,016			-
Prepaid taxes		4,902			43,359
Prepaid expenses and other current assets		2,182,383			62,664
Total Current Assets		15,627,701			16,787,606
Property and equipment, net		13,597,491			13,967,964
Land use rights		2,336,847			2,303,112
Total Assets	$	31,562,039		$	33,058,682
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	3,079,576		$	2,495,776
Due to related party		85,271			-
Taxes payable		65,437			118,351
Derivative liability		5,203			5,203
Total Current Liabilities		3,235,487			2,619,330
STOCKHOLDERS' EQUITY:
Preferred stock, $0.001 par value; 1,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized; 157,356,137 and 155,522,809 shares issued and outstanding		157,356			155,523
Additional paid-in capital		31,122,422			28,390,279
Accumulated deficit		(8,143,385	)		(4,477,522	)
Accumulated other comprehensive income		5,190,159			4,262,044
Total Sunwin International Neutraceuticals, Inc. stockholders' equity		28,326,552			28,330,324
Noncontrolling interest		-			2,109,028
Total Stockholders' Equity		28,326,552			30,439,352
Total Liabilities and Stockholders' Equity	$	31,562,039		$	33,058,682

The accompanying notes are an integral part of these unaudited financial statements.

- 1 -

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

	For the Three Months Ended January 31,						For the Nine Months Ended January 31,
	2012			2011			2012			2011
Revenues	$	2,248,228		$	2,253,222		$	7,749,468		$	6,755,448
Revenues - related party		697,306			193,373			1,611,682			322,763
Total revenues		2,945,534			2,446,595			9,361,150			7,078,211
Cost of revenues		2,447,666			2,016,771			7,808,290			5,684,519
Gross profit		497,868			429,824			1,552,860			1,393,692
Operating expenses:
Loss on equity investment		-			47,787			-			143,754
Loss on disposition of property and equipment		-			1,173,200			674,675			1,173,200
Selling expenses		228,944			179,895			631,341			437,193
General and administrative expenses		1,548,942			2,152,270			3,283,012			3,593,552
Total operating expenses		1,777,886			3,553,152			4,589,028			5,347,699
Operating loss		(1,280,018	)		(3,123,328	)		(3,036,168	)		(3,954,007	)
Other income (expenses):
Gain on change in fair value of derivative liability		-			133			-			6,767
Other (expense) income		7,637			2,089			(49,419	)		2,544
Interest income		11,344			13,019			43,837			31,216
Total other (expense) income		18,981			15,241			(5,582	)		40,527
Loss from continuing operations before income taxes and noncontrolling interest		(1,261,037	)		(3,108,087	)		(3,041,750	)		(3,913,480	)
Discontinued operations:
Loss from discontinued operations		-			-			-			(135,736	)
Gain on disposal of discontinued operations		-			-			-			11,450
Total loss from discontinued operations		-			-			-			(124,286	)
Loss before income taxes and noncontrolling interest		(1,261,037	)		(3,108,087	)		(3,041,750	)		(4,037,766	)
Income taxes		(1,173	)		10,087			(1,173	)		-
Net loss		(1,262,210	)		(3,098,000	)		(3,042,923	)		(4,037,766	)
Less: loss attributable to noncontrolling interest		-			142,838			54,258			206,893
Net loss attributable to Sunwin International Neutraceuticals, Inc.	$	(1,262,210	)	$	(2,955,162	)	$	(2,988,665	)	$	(3,830,873	)
Comprehensive Income ( loss) :
Net loss		(1,262,210	)		(3,098,000	)		(3,042,923	)		(4,037,766	)
Gain on foreign currency translation		149,836			353,536			928,115			1,205,553
Total Comprehensive Loss	$	(1,112,374	)	$	(2,744,464	)	$	(2,114,808	)	$	(2,832,213	)
Basic and diluted loss per common share:
Loss from continuing operations	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.02	)
Loss from discontinued operations		(0.00	)		(0.00	)		(0.00	)		(0.00	)
Loss per common share	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.02	)
Weighted average common shares outstanding - basic and diluted		157,246,247			155,595,888			156,906,440			157,849,990

The accompanying notes are an integral part of these unaudited financial statements.

- 2 -

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Months Ended January 31,
	2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,042,923	)	$	(4,037,766	)
Less: total loss from discontinued operations		-			(124,286	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		1,102,324			1,097,511
Gain on change in fair value of derivative liability		-			(6,767	)
Amortization of land use right		41,435			39,440
Loss on disposition of property and equipment		674,675			1,173,036
Loss on equity investment		-			143,754
Stock issued in exchange for services		628,132			138,750
Allowance for doubtful accounts		(164,338	)		569,728
Changes in operating assets and liabilities:
Accounts receivable and notes receivable		315,387			(197,075	)
Accounts receivable - related party		(264,984	)		45,106
Inventories		(588,079	)		1,005,661
Due from related party		(3,128,911	)		-
Prepaid expenses and other current assets		(2,083,525	)		(58,574	)
Loans receivable		(2,950,896	)		(501,603	)
Tax receivable		39,213			-
Accounts payable and accrued expenses		494,629			196,244
Taxes payable		(55,833	)		(39,602	)
NET CASH USED IN CONTINUING OPERATIONS		(8,983,694	)		(307,871	)
Net cash provided by discontinued operations		-			10,713
NET CASH USED IN OPERATING ACTIVITIES		(8,983,694	)		(297,158	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash used in equity acquisition		(626,125	)		-
Proceeds from disposal of property and equipment		-			39,462
Purchases of property and equipment		(950,307	)		(526,966	)
Net cash used in discontinued operations		-			(210	)
NET CASH USED IN INVESTING ACTIVITIES		(1,576,432	)		(487,714	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Advance due to related party		83,875			-
Proceeds from exercise of warrants		-			112,449
NET CASH PROVIDED BY FINANCING ACTIVITIES		83,875			112,449
EFFECT OF EXCHANGE RATE CHANGES ON CASH		154,887			359,425
NET CHANGE IN CASH		(10,321,364	)		(312,998	)
Cash at the beginning of the period		10,563,413			10,416,522
Cash at the end of the period	$	242,049		$	10,103,524
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	$	1,173		$	14,478
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares cancelled in disposal of subsidiary	$	-		$	3,674,716

The accompanying notes are an integral part of these unaudited financial statements.

- 3 -

NOTE 1 - ORGANIZATION AND OPERATIONS

DESCRIPTION OF BUSINESS

Sunwin International Neutraceuticals, Inc., a Nevada corporation, and its subsidiaries are referred to in this report as “we”, “us”, “our”, or “Sunwin”.

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines. Except for the U.S.-based operations at Sunwin USA which we account for as an equity investment, substantially all of our operations are located in the People’s Republic of China (the “PRC”). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers. Our operations are organized into two operating segments related to our Stevioside and Chinese Medicine product lines.

In June 2010 we elected to streamline our product offerings to focus on our core business of producing and selling stevia and other herb-based products, including herb extracts and herb medicines. Consequently, we have exited all business activities related to our veterinary medicines and sold our 100% interest in our Shengya Veterinary Medicine subsidiary to Mr. Laiwang Zhang, our President and Chairman of the Board of Directors on July 31, 2010. See Note 10 – Discontinued Operations.

On December 2, 2011, we signed a supply agreement with Domino Foods, Inc. (“Domino Sugar”) to sell our Reb A 60 and higher grades of stevia. This new supply agreement is effective through December 31, 2012, and will be renewable thereafter from month to month unless terminated by either party upon 30 days notice. The agreement provides that quantities and prices for the stevia ingredients will be included in purchase orders which will include agreed on pricing. Payments will be made on account on a net 30 days basis.

Stevioside Segment

Stevioside, whose content includes rebaudioside, is an all natural, low calorie sweetener extracted from the leaves of the stevia rebaudiana plant. Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represents 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors. Qufu Shengwang manufactures and sells stevia -based fertilizers and feed additives.

On September 30, 2011, Qufu Shengwang purchased the 40% equity interest in Qufu Shengwang owned by our Korean partners, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of January 31, 2012 has been eliminated to reflect our 100% interest in Qufu Shengwang. We plan to use these assets to build a new stevioside production line when market demand outgrows our current production capacity, which we expect to occur in fiscal 2014 if not earlier.

Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals. Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 98.

- 4 -

Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned Sunwin USA in the marketing and worldwide distribution of our stevioside based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA. In exchange WILD Flavors agreed to provide Sunwin USA with sales, marketing, logistics and supply chain management, product development and regulatory services valued at $1,000,000 over a period of two years beginning on February 5, 2009.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation.

These unaudited consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2011 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the nine months ended January 31, 2012 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

Our consolidated financial statements include the accounts for the parent company and all our wholly owned and majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Our subsidiaries include the following:

- Qufu Natural Green;

- Qufu Shengren;

- Qufu Shengwang; and

- Sunwin Tech.

We discontinued veterinary segment in June 2010. The assets, liabilities and results of operations of the discontinued veterinary segment are classified as Discontinued Operations for all periods presented.

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment, the allowance for doubtful accounts and the fair value of embedded derivatives related to the outstanding warrants to purchase our common stock. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of January 31, 2012, we held $200,830 of our cash and cash equivalents with commercial banking institutions in the PRC, and $41,219 with banks in the United States. As of April 30, 2011, we held $10,532,233 of our cash and cash equivalents with commercial banking institution in PRC, and $31,180 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through January 31, 2012.

- 5 -

ACCOUNTS RECEIVABLE

Accounts receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At January 31, 2012 and April 30, 2011, the allowance for doubtful accounts was $966,886 and $1,098,240, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

LONG-LIVED ASSETS

We review and evaluate on an annual basis our long-lived assets, including property and equipment and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates. We conducted an impairment evaluation of our long-lived assets during this quarter and found that there was no impairment as of January 31, 2012.

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at January 31, 2012 and April 30, 2011 amounted to $65,437 and $118,351, respectively, consisting primarily of VAT taxes payable.

DERIVATIVE LIABILITY

We issued a total of 10,793,750 common stock purchase warrants exercisable at $0.65 per share in connection with an offering of our equity securities in 2007. On February 20, 2009, our Board of Directors approved the permanent reduction in the exercise price of these warrants to $0.15 per share. At January 31, 2012 and April 30, 2011, 22,725 warrants were outstanding, and these warrants will expire March 26, 2012. The exercise price of the warrants is subject to reset adjustment in the event of price reduction. If we issue or sell shares of our common stock for an amount less than the exercise price per share, the exercise price of the warrants is reduced to equal the new issuance price of those shares. The outstanding warrants have been determined to not be indexed to our stock and are carried at their fair value as a derivative liability. For the nine months ended January 31, 2012 and 2011, the change in fair value of the derivative liability was not material.

- 6 -

We determined the fair value of the warrants at each reporting date using the Black-Scholes Option Pricing Model based on the following assumptions and key inputs for each series of warrants and reporting date:

	January 31, 2012			April 30, 2011
Dividend Yield		0	%		0	%
Volatility		105	%		107	%
Risk Free Rate		0.04	%		0.22	%
Expected Term (Years)		0.14			0.89
Asset Price	$	0.29		$	0.36
Exercise Price	$	0.15		$	0.15

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC Section 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC Section 820-10-35-37 to measure the fair value of our financial instruments. ASC Section 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC Section 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC Section 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Section 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.

With the exception of derivative liabilities, we do not have any other assets or liabilities measured at fair value on a recurring or a non-recurring basis.

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC Section 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.

BASIC AND DILUTED EARNINGS PER SHARE

Pursuant to ASC Section 260-10-45, basic income (loss) per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations.

At January 31, 2012 and 2011 outstanding purchase warrants which could have resulted in the issuance of 22,725 additional common shares, was anti-dilutive as we reported a net loss applicable to our common shareholders for both periods; additionally, outstanding purchase warrants which could have resulted in the issuance of 26,666,666 additional common shares were also anti-dilutive as the exercise price of the warrants exceeded the average market price. As a result, basic loss per share was equal to diluted loss per share for the three and nine months ended January 31, 2012 and 2011.

- 7 -

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

Our functional currency is the Chinese Renminbi (“RMB”). In accordance with ASC 830-20-35, the financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2011	RMB 6.4918 to $1.00
As of January 31, 2012	RMB 6.2873 to $1.00

Nine months ended January 31, 2012	RMB 6.3920 to $1.00
Nine months ended January 31, 2011	RMB 6.7153 to $1.00

Three months ended January 31, 2012	RMB 6.3317 to $1.00
Three months ended January 31, 2011	RMB 6.6245 to $1.00

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At January 31, 2012, we had $200,830 on deposit in China, which is not insured. We have not experienced any losses in such accounts through January 31, 2011.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

STOCK BASED COMPENSATION

We account for the grant of stock, stock options, warrants and restricted stock awards in accordance with ASC Section 718, “Compensation - Stock Compensation” and the applicable provisions of ASC Section 505, “Equity”, which requires entities to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying statements of operations. Research and development costs are incurred on a project specific basis. Research and development cost were $158,018 and $240,080 for the nine months ended January 31, 2012 and 2011, respectively.

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

- 8 -

RECENT ACCOUNTING PRONOUNCEMENTS

In September 2011, the FASB issued Accounting Standards Update ("ASU") No. 2011-08, Intangibles – Goodwill and Other, which simplifies how an entity is required to test goodwill for impairment. This ASU would allow an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under the ASU, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The ASU includes a number of factors to consider in conducting the qualitative assessment. The ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. The adoption of ASU 2011-08 did not have an impact on our consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The presentation option under current GAAP to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity has been eliminated. The amendments in this Update should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted because compliance with amendments is already permitted. We already comply with this presentation.

In December 2010, the FASB issued ASU No. 2010-29, Disclosure of Supplementary Pro Forma Information for Business Combinations (“ASC 805”). The objective of this standard is to address diversity in practice about the interpretation of the pro forma revenue and earnings disclosure requirements for business combinations. This standard specifies that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. This standard also expands the supplemental pro forma disclosures under ASC 805 to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. This standard is effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. Early adoption is permitted. The adoption of ASU 2010-29 did not have an impact on our consolidated financial statements.

In December 2010, the FASB issued ASU No. 2010-28, Intangibles — Goodwill and Other (ASC 350): When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts. The objective of this standard is to address questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the test is passed in those circumstances because the fair value of their reporting unit is greater than zero. The amendments in this standard modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. This standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. Early adoption is not permitted. The adoption of ASU 2010-28 did not have an impact on our consolidated financial statements.

In July 2010, the FASB issued ASU No. 2010-20, Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses, requiring companies to improve their disclosures about the credit quality of their financing receivables and the credit reserves held against them. The extra disclosures for financing receivables include aging of past due receivables, credit quality indicators, and the modifications of financing receivables. This guidance is effective for interim and annual periods ending on or after December 15, 2010. There was no material impact on our consolidated financial position, results of operations or cash flows.

In January 2010, the FASB issued ASU No. 2010-02, Accounting and Reporting for Decreases in Ownership of a Subsidiary, which clarifies the scope of the guidance for the decrease in ownership of a subsidiary in ASC Topic 810, “Consolidations,” and expands the disclosures required for the deconsolidation of a subsidiary or de-recognition of a group of assets. This guidance was effective on January 1, 2010. We have adopted this guidance and it did have an effect on the accompanying consolidated financial statements.

In January 2010, the FASB issued ASU No. 2010-01, Accounting for Distributions to Shareholders with Components of Stock and Cash, which clarifies that the stock portion of a distribution to stockholders that allows them to elect to receive cash or stock with a potential limitation on the total amount of cash that all stockholders can elect to receive in the aggregate is considered a share issuance that is reflected in earnings per share prospectively and is not a stock dividend for purposes of applying ASC Topic 505, “Equity,” and ASC Topic 260, “Earnings Per Share.” This guidance is effective for interim and annual periods ending on or after December 15, 2009, and should be applied on a retrospective basis. The application of the requirements of this guidance had no effect on our consolidated financial statements.

- 9 -

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

NOTE 3 - INVENTORIES

At January 31, 2012 and April 30, 2011, inventories consisted of the following:

	January 31, 2012			April 30, 2011
	(unaudited)
Raw materials	$	1,019,473		$	736,533
Work in process		190,763			179,585
Finished goods		3,546,350			3,099,869
		4,756,586			4,015,987
Less: reserve for obsolete inventory		(722,556	)		(688,073	)
	$	4,034,030		$	3,327,914

NOTE 4 - PROPERTY AND EQUIPMENT

At January 31, 2012 and April 30, 2011, property and equipment consisted of the following:

	Estimated Life	January 31, 2012			April 30, 2011
		(unaudited)
Office Equipment	5-7 Years	$	43,157		$	39,568
Auto and Trucks	10 Years		873,826			796,099
Manufacturing Equipment	20 Years		11,328,271			11,364,168
Buildings	20 Years		7,194,929			6,607,434
			19,440,183			18,807,269
Less: Accumulated Depreciation			(5,842,692	)		(4,839,305	)
		$	13,597,491		$	13,967,964

For the nine months ended January 31, 2012 and 2011, depreciation expense totaled $1,102,324 and $1,097,511, respectively. During the second quarter of fiscal 2012, we disposed of obsolete manufacturing equipment and incurred a loss on disposition of $674,675, which is included in our statement of operations.

NOTE 5- LAND USE RIGHTS

Intangible assets consisted of the following:

	Estimated Life	January 31, 2012			April 30, 2011
		(unaudited)
Land Use Right	42.15 Years	$	2,528,748		$	2,448,171
Less: Accumulated Amortization			(191,901	)		(145,059	)
		$	2,336,847		$	2,303,112

For the nine month periods ended January 31, 2012 and 2011, amortization expense amounted to $41,435 and $39,440, respectively.

- 10 -

NOTE 6 – LOAN RECEIVABLE

In December 2011, we entered into a short-term loan agreement with Shandong Anda Biotech Co., Ltd. ( "Shandong Anda"), a third party. According to the terms of the agreement, we agreed to lend Shandong Anda approximately $3,181,016 (RMB 20,000,000). The loan will be due on December 18, 2012 and bears no interest. Shandong Anda is a major supplier of stevia leaves to the Company.

During the third quarter of fiscal 2011 we loaned $327,245 to a subsidiary of China Direct Investments, Inc., our corporate management services provider, which is comprised of $312,000 in principal and $15,245 in accrued interest. Both the principal and accrued interest are due on demand.

NOTE 7 - RELATED PARTY TRANSACTIONS

Accounts Receivable – related party

At January 31, 2012 and April 30, 2011, we reported $480,626 and $204,664 in accounts receivable – related party, respectively. Accounts receivable – related party reflected amounts due from Qufu Shengwang Import and Export Corporation, a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, for merchandise that has been delivered. Total related party revenues for the three months ended January 31, 2012 and 2011 were $697,306 and $193,373, respectively, and for the nine months ended January 31, 2012 and 2011 were $1,611,682 and $322,763, respectively.

Due from related parties

In November 2011, we entered into a loan agreement with Shandong Shengwang Pharmaceutical Co., Ltd., a limited liability company organized under the laws of the PRC ("Pharmaceutical Corporation"), in which Mr. Laiwang Zhang, our president and chairman holds a majority interest. According to the terms of the agreement, we agreed to lend Pharmaceutical Corporation approximately $3,181,016 (RMB 20,000,000). The loan had an original due date of November 20, 2012,and bears no interest. Pharmaceutical Corporation was going to use the money to acquire the land use rights and Sunwin would have the beneficial ownership of the acquired land. As a result of restrictions by the government in the city in which the land is located, which prohibits bidding on land use rights by foreign owned companies such as ours, we requested Pharmaceutical Corporation obtain the rights for us. On March 16, 2012, the loan agreement was amended to change the due date of the loan to April 20, 2012 since Sunwin has decided not to bid for the land use rights at this time.

Due to related parties

We pay management fees to Pharmaceutical Corporation. For the nine month ended January 31, 2012, we paid Pharmaceutical Corporation $750,939 for management compensation, which is included in general and administrative expense. At January 31, 2012, we owed Pharmaceutical Corporation $85,271 for management fee compensation. Pharmaceutical Corporation also orally agreed to waive the management fees it charged us for fiscal 2011.

NOTE 8 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at January 31, 2012 and April 30, 2011 totaled $2,182,383 and $62,664, respectively. As of January 31, 2012, prepaid expenses and other current assets includes $1,923,878 deposit for apartment units, $198,373 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us and $60,132 for employee advances. We recognize prepayments in inventory as suppliers make delivery of goods, and as an expense when providers provide the services.

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for use by certain employees. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units are expected to be delivered by December 30, 2012. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066, upon completion of the ownership documents and transfer of the apartment units to us-see Note 12.

Prepaid expense and other current assets at April 30, 2011 of $62,664 represent prepayments to suppliers for merchandise that had not been shipped to us, services that had not been provided to us and employee advances.

- 11 -

NOTE 9 - STOCKHOLDERS' EQUITY

On May 9, 2011, we issued Yefu Sun 333,328 shares of our common stock for legal services pursuant to an agreement we entered into with Mr. Sun in December 2009 and amended in March 2010. The shares were part of our agreement to issue Mr. Sun a total of 1,000,000 shares as compensation for services over a 24 month period because there was no performance commitment at the date of the agreement. We recognized compensation expense based on the fair value of our common stock at each interim reporting date. In connection with this share issuance, $103,332 in stock-based consulting expense was recognized during the nine months ended January 31, 2012.

On April 22, 2011 we entered into a consulting agreement with China Direct Investments, Inc. (“CDI”) to perform consulting services for fiscal 2012 and agreed to a consulting fee of 1,500,000 shares of our common stock. On May 6, 2011 we issued 1,000,000 shares of our common stock valued at $343,000 to CDI. On November 21, 2011 we issued another 500,000 shares of our common stock valued at $181,800 to CDI as consulting expenses pursuant to this agreement. During the nine months ended January 31, 2012, we recognized a total of $524,800 in stock-based consulting expenses. We recognized $138,750 in stock-based consulting expenses during the nine months ended January 31, 2011. These amounts are reflected in general and administrative expenses in the accompanying consolidated statements of operations.

During the third quarter of fiscal 2011, we issued 749,655 shares of our common stock upon the exercise of purchase warrants at $0.15 per share providing proceeds to us of $112,449. A summary of the changes to our outstanding stock warrants during the nine months ended January 31, 2012 is as follows:

	Shares		Weighted Average Exercise Price
Outstanding at April 30, 2011		26,689,391	$	0.35
Granted		-		-
Exercised		-		-
Forfeited		-		-
Warrants exercisable at January 31, 2012 (unaudited)		26,689,391	$	0.35

The following information applies to all warrants outstanding at January 31, 2012:

		Warrants Outstanding			Warrants Exercisable
Exercise Prices		Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$	0.15	22,725	0.14	$0.15	22,725	$0.15
$	0.35	26,666,666	2.00	$0.35	26,666,666	$0.35
		26,689,391		$0.35	26,689,391	$0.35

NOTE 10 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the nine months ended January 31, 2012 and 2011, we operated in two reportable business segments - (1) natural sweetener (stevioside) and (2) traditional Chinese medicines, organic herbal medicine, neutraceutical products, and veterinary medicines prepared from organic herbal ingredients. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations.

- 12 -

Condensed financial information with respect to these reportable business segments for the three months ended January 31, 2012 and 2011 is as follows:

	Chinese Medicines						Stevioside						Corporate and Other						Consolidated
(Unaudited)	2012			2011			2012			2011			2012			2011			2012			2011
Net revenues	$	812,056		$	632,499		$	2,133,478		$	1,814,096		$	-		$	-		$	2,945,534		$	2,446,595
Interest income	$	7,741		$	2,080		$	991		$	9,336		$	2,612		$	1,603		$	11,344		$	13,019
Depreciation and amortization	$	19,495		$	55,064		$	371,111		$	308,590		$	-		$	-		$	390,606		$	363,654
Loss from continuing operations before taxes and noncontrolling interest	$	(602,387	)	$	(542,158	)	$	(446,579	)	$	(2,552,840	)	$	(212,071	)	$	(13,089	)	$	(1,261,037	)	$	(3,108,087	)
Segment assets	$	8,753,938		$	4,167,604		$	22,407,301		$	28,329,965		$	400,800		$	561,113		$	31,562,039		$	33,058,682

Condensed financial information with respect to these reportable business segments for the nine months ended January 31, 2012 and 2011 is as follows:

	Chinese Medicines						Stevioside						Corporate and Other						Consolidated
(Unaudited)	2012			2011			2012			2011			2012			2011			2012			2011
Net revenues	$	2,421,481		$	1,648,034		$	6,939,669		$	5,430,177		$	-		$	-		$	9,361,150		$	7,078,211
Interest income	$	13,880		$	4,318		$	19,972		$	25,295		$	9,985		$	1,603		$	43,837		$	31,216
Depreciation and amortization	$	58,257		$	91,117		$	1,085,502		$	1,045,834		$	-		$	-		$	1,143,759		$	1,136,951
Loss from continuing operations before taxes and noncontrolling interest	$	(988,313	)	$	(734,076	)	$	(1,391,962	)	$	(3,084,109	)	$	(661,475	)	$	(95,295	)	$	(3,041,750	)	$	(3,913,480	)
Segment assets	$	8,753,938		$	4,167,604		$	22,407,301		$	28,329,965		$	400,800		$	561,113		$	31,562,039		$	33,058,682

NOTE 11 – DISCONTINUED OPERATIONS

In June 2010, as part of our strategy to streamline our product offerings to focus on our core business of producing and selling stevia and other herb-based products, including herb extracts and herb medicines, and also to eliminate subsidiaries with minimal operations, we elected to sell our Veterinary Medicine division and to dissolve Sunwin Canada and reclassified the subsidiaries as “Discontinued Operations” beginning with our financial statements for the first quarter of fiscal 2011. The assets and liabilities, as well as the results of operations, of the discontinued subsidiary are classified as “Discontinued Operations” for the three and nine months ended January 31, 2012 and 2011.

The following tables set forth the financial results of the discontinued operations for the three and nine months ended January 31, 2012 and 2011:

	Three Months Ended				Nine Months Ended
	January 31,				January 31,
	2012		2011		2012		2011
Revenues	$	-	$	-	$	-	$	326,284
Cost of Revenue		-		-		-		203,489
Gross profit		-		-		-		122,795
Operating expenses		-		-		-		258,531
Loss from discontinued operations		-		-		-		(135,736	)
Gain from disposal of discontinued operations		-		-		-		11,450
Total loss from discontinued operations	$	-	$	-	$	-	$	(124,286	)

- 13 -

NOTE 12-COMMITMENTS AND CONTINGENCIES

NOTE 13 - SUBSEQUENT EVENTS

Strategic Plans to dispose of Chinese Medicine Segment

Currently we are evaluating alternatives as to the potential disposition of the Chinese Medicines segment to further streamline our product offering and focus our business on producing and selling high-quality stevia products. The exit strategy contemplated for the Chinese Medicines segment has also been influenced by our concerns on the profitability of this segment in the near future.

- 14 -

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the preceding unaudited consolidated financial statements and footnotes and our 2011 Annual Report on Form 10-K for fiscal year ended April 30, 2011.

OVERVIEW

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines. Substantially all of our operations are located in the PRC. We have built an integrated company with the production and distribution capabilities designed to meet the needs of our customers.

During fiscal 2012 and 2011 our operations were organized in two operating segments related to our product lines:

	-	Stevioside, and
	-	Chinese Medicine.

Recent Developments

On September 30, 2011, Qufu Shengwang repurchased the 40% equity interest in Qufu Shengwang owned by Korea Stevia Company, Limited, for $626,125 in cash. As a result of this purchase, we own 100% of the equity interest in Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of October 31, 2011 has been eliminated to reflect our 100% interest in Qufu Shengwang. We plan to use these assets to build a new stevioside production line when market demand outgrows our current production capacity, which we expect to occur by fiscal 2014 if not earlier.

In furtherance of our efforts to move toward production of organic, all natural and low calorie products and to enhance our international position and market penetration as a Stevia producer along with our distribution partners around the world, we underwent an extensive audit in 2011 by CERES GmbH, an international organization that specializes in inspection and certification in the areas of organic farming and food processing. Upon completion of their audit in November 2011, CERES GmbH notified us that our stevia extracts production process had been certified organic and free of synthetic chemical inputs and uses clean and sanitized procedures that avoid chemical contamination under standards established by the USDA National Organic Program and European Commission (EC) 834/2007 and EC 889/2008.

On December 2, 2011, we signed a supply agreement with Domino Foods, Inc. ("Domino Sugar") to sell our Reb A 60 and higher grades of stevia. This new supply agreement is effective through December 31, 2012, and will be renewable thereafter from month to month unless terminated by either party upon 30 days notice. We believe that this supply agreement will enable us to provide a wide range of our FDA GRAS affirmed stevia extracts to Domino Sugar for use in products such as “Domino Lite”, a new lower calorie blend of sugar and stevia now available in the United States. In addition, we expect that the agreement will enable Domino Sugar to offer our stevia extracts and sweetening solutions made with Sunwin Stevia™ to Domino Sugar's network of food and beverage industry clients in North America and Europe.

Stevioside Segment

Stevioside and rebaudioside are all natural low calorie sweeteners extracted from the leaves of the stevia rebaudiana plant. Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets. Stevioside can be used to replace sugar in beverages and foods, including those that require baking or cooking where synthetic chemical based sweetener replacements are not suitable.

Steviosin is a natural low calorie stevioside extract for medicinal use, containing rebaudioside A at 90% with the total steviol glycosides meeting or exceeding 95% on a dry weight basis. Steviosin is used as an alternative sweetener in the pharmaceutical production in China.

OnlySweet™ is an all natural, zero calorie, dietary supplement comprised of three natural ingredients, including stevioside. Based on our strategy to develop new products in collaboration with Domino Sugar that contain our stevia products, we are evaluating our strategy for the sale and distribution of OnlySweet™.

- 15 -

In an effort to meet the international food safety standards mandated by larger consumer product companies that we expect to target as customers in the future, we have made capital investments to enhance our manufacturing facilities, equipment and documentation systems, changed certain manufacturing processes and carried out additional personnel training in order to meet these standards. These investments allowed us to meet the HACCP System Certification, ISO 9001:2008 Certification and ISO 22000:2005 Food Safety Certification. We obtained these certifications in November, 2010.

Chinese Medicine Segment

In our Chinese Medicine segment, we manufacture and sell approximately 325 different extracts, including traditional Chinese medicine extracts and purified extracts, which may include active parts and monomer compounds such as soy isofavone.

We are currently evaluating alternatives as to the potential disposition of the Chinese Medicines segment to further streamline our product offering and focus our business on producing and selling high-quality stevia products. The exit strategy contemplated for the Chinese Medicine segment has also been influenced by our concerns on the profitability of this segment in the near future. The competition in Chinese Medicine market has strengthened over the past few months, causing further reductions in our already low margins in this segment compared to last year. In addition, the Chinese government continues to issue more regulations covering the supply of Chinese herbal raw materials and has increased the regulatory manufacturing standards on this segment. These measures are expected to further increase our raw materials and production costs in the coming quarters and beyond. The revenues generated from this segment have slightly improved during the first nine months of fiscal 2012, primarily due to expansion of customer base. However, this segment is currently operating at full capacity and we do not expect significant growth potential from this segment in the near future.

Discontinued Operations

In June 2010, we elected to streamline our product offerings to focus on our core business of producing and selling stevia and other herb-based products, including herb extracts and herb medicines. On July 31, 2010, we exited all business activities related to our veterinary medicine business through the sale of our 100% interest in our Shengya Veterinary Medicine subsidiary to Mr. Laiwang Zhang, our president and chairman of the Board of Directors, in exchange for 7,818,545 shares of our common stock owned by Mr. Zhang, valued at $3.7 million, which we subsequently cancelled. We recorded a gain on the sale of this business in the amount of approximately $11,000. As a result of the above-referenced transaction, the assets, liabilities, and results of operations of the discontinued subsidiary have been reclassified as “Discontinued Operations” for fiscal 2012 and 2011. Accordingly, the discussion of our results of operations that follows is based upon our continuing Stevioside and Chinese Medicine operations.

OUR PERFORMANCE

Three months ended January 31, 2012 compared to same period in 2011

Our total revenues of $2.9 million in the third quarter of fiscal 2012 increased by $0.5 million, or 20.4%, from $2.4 million for the same period in fiscal 2011, while our gross margin decreased slightly to 16.9% from 17.6% over the same period in fiscal 2011. One of the drivers for the increase in total revenues was due primarily to related party sales which increased by $0.5 million in the third quarter of fiscal 2012 as compared to the same period in fiscal 2011. Our sales revenues, excluding revenues from related party, remained basically the same at $2.2. million in the third quarter of fiscal 2012 as compared to the same period in fiscal 2011. Our operating expenses in the third quarter of fiscal 2012 decreased by approximately $0.6 million, after exclusion of $1.2 million of loss on disposition of property and equipment incurred during the same period in fiscal 2011. Our net loss from continuing operations for the third quarter of fiscal 2012 was $1.3 million, compared to $3.1 million for the same period in fiscal 2011. The decline in our operating performance for the third quarter of fiscal 2012 was due primarily to higher cost of raw materials and selling expenses.

Nine months ended January 31, 2012 compared to same period in 2011

Our total revenues of $9.4 million in the first nine months of fiscal 2012 increased by $2.3 million, or 32.3%, compared with the same period in fiscal 2011, while our gross margin decreased to 16.6% from 19.7% over the same period in fiscal 2011. One of the drivers for the increase in total revenues is due primarily to related party sales which increased by $1.3 million in the first nine months of fiscal 2012, as compared to the same period in fiscal 2011. Our sales revenues, excluding revenues from related party, increased by $1.0 million, or 14.7%, in the first nine months of fiscal 2012 as compared to the same period in fiscal 2011. Our operating expenses during the first nine months of fiscal 2012 decreased by approximately $0.2 million, after excluding $0.7 million and $1.2 million for the first nine months of 2011 and 2012, respectively, for losses on disposition of obsolete property and equipment. Our net loss from continuing operations for the first nine months of fiscal 2012 was $3.0 million, compared to $3.7 million for the same period in fiscal 2011.

- 16 -

Our operating performance in the first nine months of fiscal 2012 was driven by sales volume increase in our Chinese Medicine segment accompanied by an increase in sales volume of higher grades stevia products in our Stevioside segment. However, the actual growth of the international market, especially the U.S. market, was behind expectations as many of our manufacturing customers have ended up with higher inventories, and have reduced their purchases of raw materials.

While we have broadened our stevia product offerings to include a number of higher quality stevia grades needed in new product formulations we are developing to introduce to the U.S. and European food and beverage industry, the demand for higher grade stevia products has yet to materialize to the degree we had anticipated, and thus our sales volume in higher grade stevia products has remained low for the first nine months of fiscal 2012. Furthermore, we continue to encounter strong competition from smaller Chinese vendors who supplied cheaper and lower grade ingredients and stevioside extracts for export to Southeast Asia. As a result, some of our customers reduced purchases of our higher quality grades of stevia in favor of lower quality stevia grades, a trend which began in 2010. The increase in revenues in our Chinese Medicine was due primarily to moderate increases in pricing during the first nine months of fiscal 2012 and, more recently, increased livestock breeding resulting in higher demand for these products. The decline in our operating performance for the first nine months of fiscal 2012 was due primarily to lower gross margins in both of our operating segments primarily due to higher raw material costs.

RESULTS OF OPERATIONS

The following table summarizes our results from continuing operations for the three month periods ended January 31, 2012 and 2011:

January 31, 2012
		Chinese Medicine				Stevioside				Corporate and other		Consolidated

Total revenues	$	812,056	100.0	%	$	2,133,478	100.0	%	$	-	$	2,945,534	100.0	%
Cost of revenues		730,835	90.0	%		1,716,831	80.5	%		-		2,447,666	83.1	%
Gross profit		81,221	10.0	%		416,647	19.5	%		-		497,868	16.9	%

Total operating expenses		691,143	85.1	%		872,060	40.9	%		214,683		1,777,886	60.4	%
Other income(expenses)		7,535	0.9	%		8,834	0.4	%		2,612		18,981	0.6	%

Loss from continuing operations before
taxes and noncontrolling interest	$	(602,387)	-74.2	%	$	(446,579)	-20.9	%	$	(212,071)	$	(1,261,037)	-42.8	%

January 31, 2011
	Chinese Medicine				Stevioside				Corporate and other		Consolidated
Total revenues	$	632,499	100.0	%	$	1,814,096	100.0	%	$	-	$	2,446,595	100.0	%
Cost of revenues		567,176	89.7	%		1,449,595	79.9	%		-		2,016,771	82.4	%
Gross profit		65,323	10.3	%		364,501	20.1	%		-		429,824	17.6	%

Total operating expenses		609,748	96.4	%		2,928,579	161.4	%		14,825		3,553,152	145.2	%
Other income (expenses)		2,267	0.4	%		11,238	0.6	%		1,736		15,241	0.6	%

Loss from continuing operations before
taxes and noncontrolling interest	$	(542,158)	-85.7	%	$	(2,552,840)	-140.7	%	$	(13,089)	$	(3,108,087)	-127.0	%

- 17 -

The following table summarizes our results from continuing operations for the nine month periods ended January 31, 2012 and 2011:

January 31, 2012
		Chinese Medicine				Stevioside				Corporate and other		Consolidated
Total revenues	$	2,421,481	100.0	%	$	6,939,669	100.0	%	$	-	$	9,361,150	100.0	%
Cost of revenues		2,201,940	90.9	%		5,606,350	80.8	%		-		7,808,290	83.4	%
Gross profit		219,541	9.1	%		1,333,319	19.2	%		-		1,552.860	16.6	%

Total operating expenses		1,159,373	47.9	%		2,758,195	39.8	%		671,460		4,589,028	49.0	%
Other income (expenses)		(48,481)	-3	%		32,914	0.5	%		9,985		(5,582)	-0.1	%

Loss from continuing operations before
taxes and noncontrolling interest	$	(988,313)	-40.8	%	$	(1,391,962)	-20.1	%	$	(661,475)	$	(3,041,750)	-32.5	%

January 31, 2011
	Chinese Medicine				Stevioside				Corporate and other		Consolidated
Total revenues	$	1,648,034	100.0	%	$	5,430,177	100.0	%	$	-	$	7,078,211	100.0	%
Cost of revenues		1,399,653	84.9	%		4,284,866	78,9	%		-		5,684,519	80.3	%
Gross profit		248,381	15.1	%		1,145,311	21.1	%		-		1,393,692	19.7	%

Total operating expenses		989,319	60.0	%		4,254,715	78.4	%		103,665		5,347,699	75.6	%
Other income		6,862	0.4	%		25,295	0.5	%		8,370		40,527	0.6	%

Loss from continuing operations before
taxes and noncontrolling interest	$	(734,076)	-44.5	%	$	(3,084,109)	-56.8	%	$	(95,295)	$	(3,913,408)	-55.3	%

Revenues

Total revenues in the third quarter of fiscal 2012 increased by $0.5 million, or 20.4%, as compared to the same period in fiscal 2011. Stevioside revenues, which comprised 72.4% and 74.1% of our revenues for the third quarter of fiscal 2012 and fiscal 2011, respectively, increased by approximately $0.3 million, or 17.6%, while revenues in our Chinese Medicine segment increased by $0.2 million, or 28.4%.

The increase in Stevioside revenues was due primarily to higher sales volume of both higher and lower grades stevia products in the domestic market to Chinese manufacturers who use our products as raw materials, accompanied with a moderate increase in sales volume in the international market. However, the demand growth for our higher grade stevia products continues to improve at a slower pace than anticipated in international markets, especially in the U.S., where the adoption rate for stevia in the food and beverage has been slower than expected, and in the EU, where full approval of stevia did not take place until the fourth quarter of calendar 2011. International demand growth for our lower grade stevia products as raw materials were hampered by a reduction in purchases due to higher inventory levels at many manufacturers that anticipated higher sales volumes in those same markets. We also experienced pricing pressure as some smaller competitors have liquidated inventories while under financial distress. The increase in Chinese Medicine revenues was due primarily to seasonally higher demand for meat and eggs, resulting in increased livestock breeding, which spurs demand for our products. The livestock breeding industry in China entered the traditional peek production cycle, in this quarter, in preparation for the annual peak consumption during the Chinese holiday season featured by New Year’s Day and Chinese Spring Festival. Our customers, many of whom are Chinese medicines producers, increased purchases of Chinese medicine raw materials from us in this quarter.

Total revenues for the first nine months of fiscal 2012 increased by $2.3 million, or 32.3%, compared to the same period in fiscal 2011. Stevioside revenues, which comprised 74.1% and 76.7% % of our revenues for the first nine months of fiscal 2012 and fiscal 2011, respectively, increased by $1.5 million, or 27.8%, while Chinese Medicine revenues increased by $0.8 million, or 46.9%.

- 18 -

The increase in Stevioside revenues was driven by higher sales volume of our higher grade Stevioside products in the domestic market, accompanied by a moderate increase in sales volume of our higher grades stevia products in the export market. In addition, the demand growth for our intermediate and higher grade stevia products was slower than anticipated in international markets, especially in the U.S., where the adoption rate for stevia in the food and beverage has been slower than expected, and in the EU, where full approval of stevia did not take place until the fourth quarter of calendar 2011.We also continue to experience significant downward pressure on pricing for some of our products as some of our smaller competitors have been required to liquidate their inventory while under financial distress. We produced 208.8 metric tons of stevioside for the first nine months of fiscal 2012 as compared to 134.6 metric tons during the same period in fiscal 2011.

The increase in Chinese Medicine revenues was due primarily to seasonally higher demand for meat and eggs, resulting in increased livestock breeding, which spurs demand for our products. The livestock breeding industry entered the traditional peek production cycle, in this quarter, in preparation for the annual peak consumption during the Chinese holiday season featured by New Year’s Day and Chinese Spring Festival during January 2012.

Cost of Revenues and Gross Margin

Cost of revenues in the third quarter of fiscal 2012 increased by $0.4 million, or 21.4%, as compared to the same period in fiscal 2011, which parallels the overall increase in the volume of sales revenues during this period. Gross margin on Stevioside segment decreased slightly during the third quarter of fiscal 2012 to 19.5%, compared to 20.1% for the same period in fiscal 2011. The Chinese Medicine gross margin remained flat at 10.0% in the third quarter of fiscal 2012, compared to 10.3% for the same period in fiscal 2011. As a result, consolidated gross margin for the third quarter of fiscal 2012 decreased slightly to 16.9%, compared to 17.6% for the same period in fiscal 2011.

Cost of revenues for the first nine months of fiscal 2012 increased by $2.1 million, or 37.4%, compared to the same period in fiscal 2011. Gross margin on Stevioside segment for the first nine months of fiscal 2012 was 19.2%, as compared to 21.1% for the same period in fiscal 2011.The lower gross margins for Stevioside was due primarily to higher costs of raw materials and increased competition in both the domestic and international markets which resulted in having to charge lower prices for our products to remain competitive. Gross margin on Chinese Medicine was 9.1% in the first nine months fiscal 2012, compared to 15.1% for the same period in fiscal 2011. The lower gross margin for Chinese Medicines was due primarily to higher raw material and energy costs. Since we purchase our raw materials on the spot market, we are unable to predict with any degree of certainty our raw material costs and their impact on gross margin in future periods. Our consolidated gross margin for the first nine months of fiscal 2012 was 16.6%, compared to 19.7% for the same period in fiscal 2011.

Total Operating Expenses

Operating expenses for the first three months of fiscal 2012 decreased by $0.6 million, or 25.3%, after exclusion of a $1.2 million loss on disposition of property and equipment incurred during the same period in fiscal 2011. The decrease was primarily due to $0.8 million reduction in general and administrative expenses for planned reductions in office and travel related expenses in the Stevioside segment, offset by an increase of $0.2 million in stock compensation expense paid primarily for consulting services.

Our operating expenses during the first nine months of fiscal 2012 decreased by approximately $0.2 million, or 6.2%, after excluding $0.7 million and $1.2 million for the first nine months of 2011 and 2012, respectively, for losses on disposition of obsolete property and equipment . After exclusion of the loss on disposition of obsolete property and equipment for both periods in 2012 and 2011, the decrease was primarily due to a $1.0 million reduction in general and administrative expenses for office and travel expenses, offset by an increase of $0.6 million in stock compensation expense paid primarily for consulting services and $0.3 million in selling and other consulting expenses.

Included in our operating expenses for the three and nine months ended January 31, 2012 was $0.8 million of management fees paid to Pharmaceutical Corporation. These management fees include performance compensation, annual salary, and bonus of the managers for calendar year 2012. As described in Note 7, Pharmaceutical Corporation is controlled by Mr. Zhang, our President and Chairman.

- 19 -

Our Outlook

We believe that there are significant opportunities for worldwide growth in our Stevioside segment, primarily in the U.S. and EU. For the rest of fiscal 2012 and beyond, we will continue to focus on our core business of producing and selling stevioside series products.

Some of the recent favorable trends in the stevia segment include:

	Chinese domestic food and beverages, particularly herbal tea manufacturers and the pharmaceutical industry, have increased the use of steviosides;
	In November 2011, the European Union authorized the use of steviol glucoside derived from the stevia plant for EU-wide use in certain foodstuffs;
	Southeast and South Asia have renewed and increased their interest in stevia, particularly high grade stevia.
	Sunwin was notified in November of 2011 that its stevia extracts production process has been certified organic under standards established by the USDA National Organic Program and European Commission (EC) 834/2007 and EC 889/2008 which will further expand the use of our organic stevia products in the food and beverage industry market in the US and Europe;
	We expect that the supply agreement we signed with Domino Sugar in December 2011 for the sale of our stevia products will further develop our market share and increase sales volumes in the stevia segment over the next year. This agreement will provide us with the opportunity to expand our sales in the U.S. consumer products market with new products that incorporate our high grade stevia extracts;
	The marketing strategy to differentiate ourselves as a producer of higher quality stevia grades and product formulations through these collaboration efforts will lead to sustainable growth in stevia sales volume in the future

Meanwhile, we are also facing challenges in competitive pricing and raw materials for the rest of fiscal 2012 and into the next fiscal year. During the first nine months of fiscal 2012, the market prices of stevioside series were impacted by fierce price competition among Chinese manufacturers. We expect the price pressure to continue for the rest of fiscal 2012 and into fiscal 2013. In addition, we anticipate the price of stevia leaves, the raw material used to produce our stevioside series products, to continue to increase in the coming harvest fall season for 2012. The expected raw materials price increase would be due to anticipated supply shortage of plants as a result of unusual dry weather during late 2011 and early 2012, which we experienced in some major stevia plantation areas including the northeastern and eastern parts of China.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate sufficient cash to meet its operational cash requirements.

At January 31, 2012 and April 30, 2011, we had working capital of $12.4 million and $14.2 million, respectively. Our cash balance at October 31, 2011 was $0.2 million, as compared to cash of $10.6 million at April 30, 2011. We believe that our existing cash and cash equivalents and internally generated funds will be sufficient to cover working capital requirements and capital expenditures during the fiscal year. Other than the approximately $0.5 million remaining on the purchase price of employee housing, we currently have no significant capital expenditure commitments.

During the third quarter of fiscal 2012 we entered into three transactions which significantly reduced our cash on hand as of January 31, 2012. These transactions included:

• In December 2011, we lent Shandong Anda Biotech Co., Ltd., a third party which is a major supplier of stevia leaves to our company, approximately $3.1 million. The short-term loan is due on December 18, 2012 and bears no interest,

• In November 2011, we lent Pharmaceutical Corporation, a related party, approximately $3.1 million. The loan had a scheduled due date of November 20, 2012, and bears no interest. Pharmaceutical Corporationwas expected to use the money to acquire land use rights and Sunwin would have the beneficial ownership of the acquired land.This short-term loan was amended on March 16, 2012 to change repayment terms to a due date of April 20, 2012 since Sunwin has decided not to bid on the land use rights. The repayment of the $3.1 loan will improve the cash on hand position in the fourth quarter of fiscal 2012, and

• In January 2012, we paid $0.8 million for management fees to Pharmaceutical Corporation, a related party.

Accounts receivable, net of allowance for doubtful accounts, and including accounts receivable from related parties, decreased by $0.1 million during the third quarter of fiscal 2012. The days’ sales outstanding in accounts receivable decreased to 69days as of January 31, 2012, as compared to 79 days as of April 30, 2011.

- 20 -

At January 31, 2012, loan receivable amounted to $3.5 million, which represented an increase of $3.0 million from April 30, 2011. In December 2011, we entered into a loan agreement with Shandong Anda Biotech Co., Ltd. ( Shandong Anda), a third party. According to the terms of the agreement, we lent Shandong Anda approximately $3.1 million. The loan will be due on December 18, 2012 and bears no interest. During the third quarter of fiscal 2011 we also loaned $0.5 million to a subsidiary of China Direct Investments, Inc., our corporate management services provider. Payment of $0.2 million was received during the third quarter of 2012. The balance of $0.3 million plus accrued interest has been extended and now is due on demand.

At January 31, 2012 inventories, net of reserve for obsolescence, amounted to $4.0 million, as compared to $3.3 million as of April 30, 2011. The increase was due primarily to purchases of raw materials for stevia products in anticipation of future demand.

Our accounts payable and accrued expenses were $3.1 million at January 31, 2012, an increase of $0.6 million from April 30, 2011. This balance, as well as that of V.A.T. taxes payable, is subject to the timing of payments for balances related to raw material purchases made in the ordinary course of business.

Cash Flows Analysis

NET CASH FLOW USED IN OPERATING ACTIVITIES:

Net cash used in operating activities was $8.9 million during the first nine months of fiscal 2012, as compared to net cash used in operating activities of $0.3 million during the first nine months of fiscal 2011. The increase resulting from cash used in operating activities was due primarily to $2.1 million increase in prepaid expenses and other current assets related to advance payments for stevia raw materials and deposits for apartment units contracted for future employees under our talent search plan sponsored by our company. We also used $0.6 million of cash to purchase raw materials inventory in stevia to support future sales, advanced $3.1 million in a short-term loan to a related party, Pharmaceutical Corporation, to acquire land use rights where we will have the beneficial ownership of the acquired land, and advanced $3.1 million to a stevia supplier in a short-term loan to secure a supply of stevia leaves for our production in anticipation of the expected shortage for this product during the fall of 2012.

NET CASH FLOW USED IN INVESTING ACTIVITIES:

Net cash used in investing activities amounted to $1.6 million during the first nine months of fiscal 2012, as compared to $0.5 million for the same period in fiscal 2011. The increase was due primarily to $0.6 million used for the purchase of the remaining 40% equity interest in Qufu Shengwang from our Korean partners, Korea Stevia Company, Limited, and $1.0 million in capital expenditures for property and equipment during fiscal 2012.

NET CASH FLOW PROVIDED BY FINANCING ACTIVITIES:

Net cash provided by financing activities amounted to $0.1 million during the first nine months of fiscal 2012, which represented advances from related party, as compared to $0.1 million from proceeds from the exercise of common stock purchase warrants for the same period in fiscal 2011.

CASH ALLOCATION BY COUNTRIES

The functional currency of our Chinese subsidiaries is the Chinese RMB. Substantially all of our cash is held in the form of RMB at financial institutions located in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash accounts at financial institutions in the PRC are not insured. We have not experienced any losses in such accounts as of January 31, 2012.

- 21 -

In 1996, the Chinese government introduced regulations which relaxed restrictions on the conversion of the RMB; however restrictions still remain, including but not limited to restrictions on foreign invested entities. Foreign invested entities may only buy, sell or remit foreign currencies after providing valid commercial documents at only those banks authorized to conduct foreign exchanges. Furthermore, the conversion of RMB for capital account items, including direct investments and loans, is subject to PRC government approval. Chinese entities are required to establish and maintain separate foreign exchange accounts for capital account items. We cannot be certain Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the RMB, especially with respect to foreign exchange transactions. Accordingly, cash on deposit in banks in the PRC is not readily deployable by us for purposes outside of the PRC. Our cash position by geographic area is as follows:

	January 31, 2012		April 30, 2011
		(Unaudited)
China	$	200,830	$	10,532,233

United States		41,219		31,180
Total	$	242,049	$	10,563,413

Off Balance Sheet Arrangements

Under SEC regulations, we are required to disclose our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, such as changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. An off-balance sheet arrangement means a transaction, agreement or contractual arrangement to which any entity that is not consolidated with us as a party, under which we have:

	•		Any obligation under certain guarantee contracts,
	•		Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets,
	•		Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to our stock and classified in stockholder’s equity in our statement of financial position, and
	•		Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

We do not have any off-balance sheet arrangements that we are required to disclose pursuant to these regulations. In the ordinary course of business, we enter into operating lease commitments, purchase commitments and other contractual obligations. These transactions are recognized in our financial statements in accordance with accepted accounting principles generally accepted in the United States of America (“U.S. GAAP”).

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with U.S. GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of our financial condition and results of operations, and which require us to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 1 to our financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

- 22 -

Estimates

Significant estimates for the periods reported include the allowance for doubtful accounts which is based on an evaluation of our outstanding accounts receivable including the age of amounts due, the financial condition of our specific customers and historical bad debt experience. This evaluation methodology has proven to provide a reasonable estimate of bad debt expense in the past and we intend to continue to employ this approach in our analysis of collectability. However, we are aware that given the current global economic crises, including that of the PRC, meaningful time horizons may change. We intend to enhance our focus on the evaluation of our customers' sustainability and adjust our estimates as may be indicted.

We rely on assumptions such as volatility, forfeiture rate, and expected dividend yield when calculating the fair value of our derivative liability related to common stock purchase warrants. We also rely on assumptions and estimates to calculate our reserve for obsolete inventory and the depreciation of property, plant and equipment. We make assumptions of expiration of our products held as inventory based on historical experience and if applicable, regulatory recommendation. We also group property plant and equipment into similar groups of assets and estimate the useful life of each group of assets.

Further, we rely on certain assumptions and calculations underlying our provision for taxes in the PRC. Assumptions and estimates employed in these areas are material to our reported financial conditions and results of operations. These assumptions and estimates have been materially accurate in the past and are not expected to materially change in the future. Actual results could differ from these estimates.

Revenue recognition

We follow the guidance of ASC 605, "Revenue Recognition,” and the Securities and Exchange Commission's Staff Accounting Bulletin (“SAB”) No. 104 and SAB Topic 13 for revenue recognition. In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

Long-lived assets

We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer,("CEO"), and our Chief Financial Officer("CFO"), to allow timely decisions regarding required disclosure.

Management, with the participation of our CEO and CFO, performed an evaluation of the effectiveness of our disclosure controls and procedures as of January 31, 2012.

Based on this evaluation our management concluded that our disclosure controls and procedures were effective as of January 31, 2012 such that the information relating to our company, required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management, including our CEO, to allow timely decisions regarding required disclosure.

- 23 -

Our management believes that our disclosure controls and procedures provide a reasonable level of assurance of achieving their objectives. Our management does not expect, however, that our disclosure controls and procedures or internal financial controls will prevent all errors or fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of our controls performed during the quarter ended January 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Risk factors describing the major risks to our business can be found under Item 1A, “Risk Factors”, in our fiscal 2011 Annual Report on Form 10-K. There has been no material change in our risk factors from those previously discussed in the fiscal 2011 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURE.

None.

ITEM 5. OTHER INFORMATION.

On November 18, 2011, we lent Pharmaceutical Corporation, a related party, approximately $3,181,016 (RMB20,000,000) under the terms of a Loan Agreement. The loan was initially due on November 20, 2012 and bears no interest. Pharmaceutical Corporation was to use the money to acquire a land use right and Sunwin would have had the beneficial ownership of the acquired land. As a result of restrictions by the government in the city in which the land is located which prohibits bidding on land use rights by foreign owned companies such as ours, we requested Pharmaceutical Corporation obtain the rights for us. Subsequent thereto, we have determined not to proceed with our plans and have requested Pharmaceutical Corporation not to proceed with the acquisitionof the land use rights. On March 16, 2012 the Loan Agreement was amended to change the due date to April 20, 2012. The foregoing description of the Loan Agreement and its amendment does not purport to be complete and are qualified in it is entirety by reference to the agreements which are filed as Exhibit 10.24 and Exhibit 10.27 to this report and incorporated herein by reference.

On December 2, 2011, we entered into a Supplier Agreement with Domino Foods, Inc. (“Domino Sugar”) to sell our Reb A 60 and higher grades of stevia. The terms of this agreement is effective through December 31, 2012, and will be renewable thereafter from month to month unless terminated by either party upon 30 days notice. The agreement provides that quantities and prices for the stevia ingredients will be included in purchase orders which will include agreed on pricing. Payments will be made on account on a net 30 days basis. The foregoing description of the Supplier Agreement does not purport to be complete and is qualified in it is entirety by reference to the agreement which is filed as Exhibit 10.25 to this report and incorporated herein by reference.

On December 16, 2011, we entered into a Loan Agreement with Shandong Anda Biotech Co., Ltd. , a third party, pursuant to which we lent Shandong Anda approximately $3,181,016 (RMB 20,000,000). The loan is due on December 18, 2012 and bears no interest. The foregoing description of the Loan Agreement does not purport to be complete and is qualified in it is entirety by reference to the agreement which is filed as Exhibit 10.26 to this report and incorporated herein by reference.

- 24 -

ITEM 6. EXHIBITS

Exhibit Number			Description of Exhibit
	10.24	*	Loan Agreement dated November 18, 2011 by and between Qufu Natural Green Engineering Co., Ltd. and Shandong ShengwangPharmaceutical Co., Ltd.
	10.25	*	Supplier Agreement dated December 2, 2012 by and between Sunwin International Neutraceuticals, Inc. and Domino Foods, Inc.
	10.26	*	Loan Agreement dated December 16, 2011 by and between Qufu Natural Green Engineering Co., Ltd. and Shandong Anda Bio-Tech Co., Ltd.
	10.27	*	Confirmation of Amendment to Loan Agreement with Shandong Shengwang Pharmaceutical Co., Ltd.
	31.2	*	Section 302 Certificate of Chief Financial Officer
	32	*	Section 906 Certificate of Chief Executive Officer and Chief Financial Officer
101.INS		**	XBRL INSTANCE DOCUMENT
101.SCH		**	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL		**	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF		**	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB		**	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE		**	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* - Filed herewith.

** - In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 to this Quarterly Report on Form 10-Q/A shall be deemed “furnished” and not “filed”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC.


Dated: March 19, 2012	By: /s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer


Dated: March 19, 2012	By: /s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer

- 25 -